Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
about
Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects.Oligonucleotide-based strategies to combat polyglutamine diseases.Gene Therapy 2017: Progress and Future Directions.Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery.Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.The role of the immune system in triplet repeat expansion diseasesAAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancerTRPC3 channels critically regulate hippocampal excitability and contextual fear memoryWidespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brainIntravenous rAAV2/9 injection for murine cochlear gene delivery.Viral vectors for therapy of neurologic diseases.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Systemic delivery of adeno-associated viral vectors.Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7.Gene suppression approaches to neurodegeneration.Nonhuman Primate Models of Neurodegenerative Disorders.
P2860
Q33600773-0ED22AA3-9EFD-429B-BE98-447AFD6E63A9Q33791247-1F5F4941-C0D0-4EA3-AC4F-2CFD5B39F3A5Q33891559-23265F66-F957-4BE5-9962-EB77BB15B95BQ33920641-10793A86-1919-4719-8C4E-FEA8BCEBB216Q34499502-0502DD10-B3B9-4C1F-A08D-42CDAF4C42CDQ35271805-588F4435-F800-4A84-A0AC-5FDB9E64AB93Q35961381-35169505-DEE9-4965-B4FB-084F5A5F09FBQ36366538-0245BF50-8199-4057-9226-BF224FD590CCQ36951265-C4F88F6C-FBD2-4B98-86AE-D3B3E225B9EBQ37051728-5A1E0FFD-A71B-4254-9582-17C3A987076CQ37382030-7BE5777C-6319-443A-85C8-4C6D428CC2B3Q38603017-9C21E3A5-90F0-4685-BF43-3DC09E70ED49Q38746238-151990DC-BF62-43EE-8749-1B05D5677D4AQ38856794-F890B564-E795-414E-B44E-8620E8DAB678Q38908933-4DF39DBA-6C53-480E-8E6B-1D2A8C9F8F20Q40558924-075674BD-08C8-492D-A3AE-80ABA0F05AB8Q41508524-4FE3BDDB-C4CA-4532-91DC-9731A29EA1C5Q42371261-B06042DD-1AB4-4330-985E-8D1F62C1B759Q47687033-C9BDEB78-54B2-45BC-8471-F5271B1FD2EB
P2860
Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intrajugular vein delivery of ...... in Huntington's disease mice.
@en
Intrajugular vein delivery of ...... in Huntington's disease mice.
@nl
type
label
Intrajugular vein delivery of ...... in Huntington's disease mice.
@en
Intrajugular vein delivery of ...... in Huntington's disease mice.
@nl
prefLabel
Intrajugular vein delivery of ...... in Huntington's disease mice.
@en
Intrajugular vein delivery of ...... in Huntington's disease mice.
@nl
P2093
P2860
P356
P1433
P1476
Intrajugular vein delivery of ...... s in Huntington's disease mice
@en
P2093
Catherine A Smith
Jodi L McBride
Randall L Clark
Timothy R Walker
P2860
P304
P356
10.1038/MT.2013.289
P577
2014-01-06T00:00:00Z